These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 27268638)

  • 21. Clinical usefulness of free light chain concentration as a tumor marker in multiple myeloma.
    Kang SY; Suh JT; Lee HJ; Yoon HJ; Lee WI
    Ann Hematol; 2005 Sep; 84(9):588-93. PubMed ID: 15883850
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Evaluation of the clinical relevance of serum measurements of free-light chains in patients with multiple myeloma].
    Shimizu K; Itoh J; Sugiura I; Tsushita K; Kosugi H; Nagura E
    Rinsho Ketsueki; 2006 Apr; 47(4):303-9. PubMed ID: 16715965
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Clinical Significance of Serum Free Light Chain and Its κ/λ Ratio in Patients with Multiple Myeloma].
    Zhao D; Jiang JQ; Lin L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Aug; 27(4):1173-1178. PubMed ID: 31418375
    [TBL] [Abstract][Full Text] [Related]  

  • 24. IgA kappa/IgA lambda heavy/light chain assessment in the management of patients with IgA myeloma.
    Boyle EM; Fouquet G; Guidez S; Bonnet S; Demarquette H; Dulery R; Herbaux C; Noel MP; Manier S; Schraen S; Onraed B; Faucompré JL; Hennache B; Petillon MO; Mathiot C; Avet-Loiseau H; Facon T; Harding SJ; Moreau P; Leleu X
    Cancer; 2014 Dec; 120(24):3952-7. PubMed ID: 25116271
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of a highly-sensitive multi-plex assay using monoclonal antibodies for the simultaneous measurement of kappa and lambda immunoglobulin free light chains in serum and urine.
    Campbell JP; Cobbold M; Wang Y; Goodall M; Bonney SL; Chamba A; Birtwistle J; Plant T; Afzal Z; Jefferis R; Drayson MT
    J Immunol Methods; 2013 May; 391(1-2):1-13. PubMed ID: 23388695
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma.
    Kyrtsonis MC; Vassilakopoulos TP; Kafasi N; Sachanas S; Tzenou T; Papadogiannis A; Galanis Z; Kalpadakis C; Dimou M; Kyriakou E; Angelopoulou MK; Dimopoulou MN; Siakantaris MP; Dimitriadou EM; Kokoris SI; Panayiotidis P; Pangalis GA
    Br J Haematol; 2007 May; 137(3):240-3. PubMed ID: 17408464
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum free light chains: diagnostic and prognostic value in multiple myeloma.
    Sthaneshwar P; Nadarajan V; Maniam JA; Nordin N; Gin Gin G
    Clin Chem Lab Med; 2009; 47(9):1101-7. PubMed ID: 19728852
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum free light chains in myeloma patients with an intact M protein by immunofixation: potential roles for response assessment and prognosis during induction therapy with novel agents.
    Mori S; Crawford BS; Roddy JV; Phillips G; Elder P; Hofmeister CC; Efebera Y; Benson DM
    Hematol Oncol; 2012 Sep; 30(3):156-62. PubMed ID: 22028144
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic value of involved/uninvolved free light chain ratio determined by Freelite and N Latex FLC assays for identification of high-risk smoldering myeloma patients.
    Henriot B; Rouger E; Rousseau C; Escoffre M; Sébillot M; Bendavid C; Minvielle S; Avet-Loiseau H; Decaux O; Moreau C
    Clin Chem Lab Med; 2019 Aug; 57(9):1397-1405. PubMed ID: 30973821
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The predictive power of serum kappa/lambda ratios for discrimination between monoclonal gammopathy of undetermined significance and multiple myeloma.
    Bergón E; Miravalles E; Bergón E; Miranda I; Bergón M
    Clin Chem Lab Med; 2005; 43(1):32-7. PubMed ID: 15653439
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum Free Light Chain Predict Overall Survival and Response to Therapy in Patients with Newly Diagnosed Multiple Myeloma.
    Meddour Y; Rahali MC; Belakehal SE; Ardjoun FZ; Chaib S; Djidjik R
    Clin Lab; 2018 Apr; 64(4):551-558. PubMed ID: 29739080
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multiple myeloma can be accurately diagnosed in acute kidney injury patients using a rapid serum free light chain test.
    Heaney JLJ; Campbell JP; Yadav P; Griffin AE; Shemar M; Pinney JH; Drayson MT
    BMC Nephrol; 2017 Jul; 18(1):247. PubMed ID: 28728609
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Detection of serum free light chain and its clinical significance in nonsecretory multiple myeloma].
    Chen HF; Hou J; Yuan ZG; Wang DX; Fu WJ; Chen YB
    Zhonghua Xue Ye Xue Za Zhi; 2008 Feb; 29(2):113-6. PubMed ID: 18681313
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The prognostic value of baseline serum free light chain in cardiac amyloidosis].
    Zhao L; Tian Z; Fang Q
    Zhonghua Nei Ke Za Zhi; 2016 Mar; 55(3):186-90. PubMed ID: 26926369
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hemodiafiltration improves free light chain removal and normalizes κ/λ ratio in hemodialysis patients.
    Bourguignon C; Chenine L; Bargnoux AS; Leray-Moragues H; Canaud B; Cristol JP; Morena M
    J Nephrol; 2016 Apr; 29(2):251-257. PubMed ID: 26022721
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic Value of Serum Free Light Chain in Multiple Myeloma.
    El Naggar AA; El-Naggar M; Mokhamer el-H; Avad MW
    Egypt J Immunol; 2015; 22(1):69-78. PubMed ID: 26415374
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inter-assay variability in automated serum free light chain assays and their use in the clinical laboratory.
    Caponi L; Romiti N; Koni E; Fiore AD; Paolicchi A; Franzini M
    Crit Rev Clin Lab Sci; 2020 Mar; 57(2):73-85. PubMed ID: 31612753
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessment of serum free light chain levels in healthy adults immediately after marathon running.
    Campbell JP; Eijsvogels TM; Wang Y; Hopman MT; Jacobs JF
    Clin Chem Lab Med; 2016 Mar; 54(3):459-65. PubMed ID: 26351935
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Automated alarm to detect antigen excess in serum free immunoglobulin light chain kappa and lambda assays.
    Urdal P; Amundsen EK; Toska K; Klingenberg O
    Scand J Clin Lab Invest; 2014 Oct; 74(7):575-81. PubMed ID: 25007050
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prediction of response and progression in multiple myeloma with serum free light chains assay: corroboration of the serum free light chain response definitions.
    Khoriaty R; Hussein MA; Faiman B; Kelly M; Kalaycio M; Baz R
    Clin Lymphoma Myeloma Leuk; 2010 Feb; 10(1):E10-3. PubMed ID: 20223721
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.